AU2017228293B2 - Rodents having a humanized Tmprss gene - Google Patents

Rodents having a humanized Tmprss gene Download PDF

Info

Publication number
AU2017228293B2
AU2017228293B2 AU2017228293A AU2017228293A AU2017228293B2 AU 2017228293 B2 AU2017228293 B2 AU 2017228293B2 AU 2017228293 A AU2017228293 A AU 2017228293A AU 2017228293 A AU2017228293 A AU 2017228293A AU 2017228293 B2 AU2017228293 B2 AU 2017228293B2
Authority
AU
Australia
Prior art keywords
gene
rodent
human
tmprss
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017228293A
Other languages
English (en)
Other versions
AU2017228293A1 (en
Inventor
Alexander O. Mujica
Lisa Purcell Ngambo
Yajun Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017228293A1 publication Critical patent/AU2017228293A1/en
Application granted granted Critical
Publication of AU2017228293B2 publication Critical patent/AU2017228293B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017228293A 2016-02-29 2017-02-27 Rodents having a humanized Tmprss gene Active AU2017228293B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301023P 2016-02-29 2016-02-29
US62/301,023 2016-02-29
PCT/US2017/019574 WO2017151453A1 (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene

Publications (2)

Publication Number Publication Date
AU2017228293A1 AU2017228293A1 (en) 2018-08-23
AU2017228293B2 true AU2017228293B2 (en) 2023-05-25

Family

ID=58264641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017228293A Active AU2017228293B2 (en) 2016-02-29 2017-02-27 Rodents having a humanized Tmprss gene

Country Status (14)

Country Link
US (5) US10070632B2 (OSRAM)
EP (2) EP3422845B1 (OSRAM)
JP (1) JP6980674B2 (OSRAM)
KR (2) KR102775366B1 (OSRAM)
CN (1) CN109068621B (OSRAM)
AU (1) AU2017228293B2 (OSRAM)
CA (1) CA3014645C (OSRAM)
DK (1) DK3422845T3 (OSRAM)
ES (1) ES2886958T3 (OSRAM)
IL (1) IL261139B (OSRAM)
PT (1) PT3422845T (OSRAM)
RU (1) RU2749715C2 (OSRAM)
SG (2) SG10202001578RA (OSRAM)
WO (1) WO2017151453A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202001578RA (en) * 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
EP3585162B1 (en) * 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
KR20200115576A (ko) 2018-01-26 2020-10-07 리제너론 파아마슈티컬스, 인크. 항-tmprss2 항체 및 항원-결합 단편
SMT202400300T1 (it) 2018-07-16 2024-09-16 Regeneron Pharma Modelli di roditori della sindrome ditra e loro utilizzo
WO2020150426A1 (en) * 2019-01-17 2020-07-23 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders
JP7772702B2 (ja) 2020-02-10 2025-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｔｍｐｒｓｓ２抗体および抗原結合断片
CN115161326B (zh) * 2021-06-21 2024-09-24 百奥赛图(北京)医药科技股份有限公司 Sost基因人源化非人动物及其构建方法和应用
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002065266A (ja) * 2000-08-28 2002-03-05 Teijin Ltd 気道特異的トリプシン様酵素およびその利用法
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1469717A4 (en) * 2001-12-20 2007-08-22 Univ California TRIPLE TRANSGENIC MOUSE MODEL FOR MORBUS ALZHEIMER
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
WO2004033630A2 (en) * 2002-10-04 2004-04-22 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof
CA2527361A1 (en) * 2003-06-11 2004-12-23 Schering Aktiengesellschaft Novel modified corin molecules having substitute activation sequences and uses thereof
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
JP5270538B2 (ja) * 2006-05-23 2013-08-21 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
GB0821624D0 (en) * 2008-11-26 2008-12-31 Eisai London Res Lab Ltd Assay
CN102482347B (zh) * 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES3010323T3 (en) 2009-10-06 2025-04-02 Regeneron Pharma Genetically modified mice and engraftment
KR102714361B1 (ko) * 2011-02-15 2024-10-11 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
KR101926442B1 (ko) 2011-10-28 2018-12-12 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
DK2770821T3 (da) 2011-10-28 2017-11-27 Regeneron Pharma Genetisk modificerede major histocompatibility-kompleks-mus
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
JP6446355B2 (ja) * 2012-04-16 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． セリンプロテアーゼ阻害剤を投与することによるインフルエンザウイルス感染を処置又は予防する方法
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
EP2863948B1 (en) * 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
KR102473555B1 (ko) 2012-09-07 2022-12-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
IL311744B2 (en) 2012-11-05 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
LT2958938T (lt) 2013-02-20 2019-07-25 Regeneron Pharmaceuticals, Inc. Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
PT4269430T (pt) 2013-09-23 2025-08-06 Regeneron Pharma Animais não-humanos com um gene humanizado de proteína reguladora de sinal
EP3138397B1 (en) 2013-10-15 2018-12-26 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
MX356809B (es) 2013-11-19 2018-06-13 Regeneron Pharma Animales no humanos que tienen un gen del factor activador de celulas b.
EP3071025B1 (en) 2013-11-19 2018-10-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
NO2785538T3 (OSRAM) 2014-05-07 2018-08-04
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
CN106604635B (zh) 2014-06-19 2020-01-14 瑞泽恩制药公司 具有人源化程序性细胞死亡1基因的非人动物
DK3223605T3 (da) 2014-11-24 2020-11-16 Regeneron Pharma Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
EP3086637B1 (en) 2014-12-05 2019-01-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
MX2017007636A (es) 2014-12-09 2018-03-28 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
KR101693243B1 (ko) 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bugge, T.H.,et al., "Type II transmembrane serine proteases." Journal of Biological Chemistry 284.35 (2009): 23177-23181. *
E. BOTTCHER-FRIEBERTSHAUSER ET AL: JOURNAL OF VIROLOGY, vol. 84, 2010, pages 5605 - 5614 *

Also Published As

Publication number Publication date
US11910787B2 (en) 2024-02-27
KR102493894B1 (ko) 2023-01-31
KR20180117122A (ko) 2018-10-26
US20170290308A1 (en) 2017-10-12
CA3014645A1 (en) 2017-09-08
ES2886958T3 (es) 2021-12-21
PT3422845T (pt) 2021-08-26
US20170245482A1 (en) 2017-08-31
WO2017151453A1 (en) 2017-09-08
EP3422845A1 (en) 2019-01-09
US10070631B2 (en) 2018-09-11
JP6980674B2 (ja) 2021-12-15
EP3422845B1 (en) 2021-06-02
SG11201807038UA (en) 2018-09-27
RU2018131152A (ru) 2020-04-01
IL261139B (en) 2022-04-01
US10863729B2 (en) 2020-12-15
IL261139A (en) 2018-10-31
US10070632B2 (en) 2018-09-11
EP3895529A1 (en) 2021-10-20
SG10202001578RA (en) 2020-04-29
US20180332831A1 (en) 2018-11-22
CA3014645C (en) 2022-10-25
KR20230021759A (ko) 2023-02-14
KR102775366B1 (ko) 2025-03-05
US20210068377A1 (en) 2021-03-11
RU2018131152A3 (OSRAM) 2020-07-13
AU2017228293A1 (en) 2018-08-23
CN109068621A (zh) 2018-12-21
RU2749715C2 (ru) 2021-06-16
CN109068621B (zh) 2021-07-20
DK3422845T3 (da) 2021-08-30
JP2019511918A (ja) 2019-05-09
US20240147971A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
AU2017228293B2 (en) Rodents having a humanized Tmprss gene
US20250041457A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
KR102650439B1 (ko) 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
AU2019360182B2 (en) Methods for targeted insertion of DNA in genes
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
KR20120099363A (ko) 탯줄 혈액으로부터의 유도 만능 줄기 세포의 생성
AU2018282072B2 (en) B4GALT1 variants and uses thereof
KR102661616B1 (ko) Gpr156 변이체 및 이들의 용도
KR102424119B1 (ko) 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물
JP2003259875A (ja) ヒト遺伝子の一塩基多型（４）
JP2003116575A (ja) 新規遺伝子及びそれにコードされる蛋白質
JP2003180359A (ja) 新規遺伝子及びそれにコードされる蛋白質
JP2002345492A (ja) 新規遺伝子及びそれにコードされる蛋白質
CA2439155A1 (en) Isolated human tumor supressor proteins, nucleic acid molecules encoding these human tumor supressor proteins, and uses thereof
JP2003135081A (ja) 新規遺伝子及びそれにコードされる蛋白質

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)